Jove
Visualize
お問い合わせ

関連する概念動画

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Goiter01:27

Goiter

Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum.

Thyroid : official journal of the American Thyroid Association·2026
Same author

A Hybrid Delphi-Inspired Expert-LLM Workflow for Efficient Evidence Screening in Systematic Reviews.

Studies in health technology and informatics·2026
Same author

What Endocrinologists Should Know About Iodine: Population Deficiency, Individual Excess and Misinformation in the United Kingdom.

Clinical endocrinology·2026
Same author

Risk Stratification Tools for Thyroid Cancer: A Systematic Review of Models Combining Ultrasound, Cytology, and Clinical Risk Factors.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies.

The lancet. Diabetes & endocrinology·2026
Same author

A response to concerns regarding the green-top guideline on the "Management of thyroid disorders in pregnancy".

Obstetric medicine·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
関連記事をすべて見る
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: May 24, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

甲状腺毒性症候群 甲状腺毒性症候群とは

Jayne A Franklyn1, Kristien Boelaert

  • 1Centre for Diabetes, Endocrinology and Metabolism, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. j.a.franklyn@bham.ac.uk

Lancet (London, England)
|March 8, 2012
PubMed
まとめ
この要約は機械生成です。

甲状腺毒性症は,しばしばグレイス病によって引き起こされ,抗甲状腺薬または放射性ヨウ素療法で治療されます. 将来の研究は,より安全で効果的な治療法のための甲状腺機能過剰症の根本的な原因に対処することを目的としています.

さらに関連する動画

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

関連する実験動画

Last Updated: May 24, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

科学分野:

  • エンドクリノロジー エンドクリノロジー
  • 内科内科は,内科の内科である.

背景:

  • 甲状腺毒性症は,特に女性において,蔓延する内分泌系疾患である.
  • グレイヴス病は最も一般的な原因で,次に毒性結節性甲状腺症および甲状腺炎が続きます.
  • 現在の治療法は,抗甲状腺薬,放射性ヨウ素療法,甲状腺切除術などです.

研究 の 目的:

  • タイロトキシコシスの現在の理解と管理をレビューする.
  • 既存の治療法の有効性と限界について議論する.
  • タイロトキシコシス研究における将来の方向性を強調する.

主な方法:

  • タイロトキシコシスに関する既存の文献のレビュー.
  • グラブス病と毒性結節性甲状腺機能過剰症の治療結果の分析.
  • 新興治療戦略の議論.

主要な成果:

  • 抗甲状腺薬 (チオナミド) は最初の治療法であり,グレイヴス病患者の約3分の1で寛解を達成します.
  • 放射性ヨウ素療法は,第一線治療としてますます使用され,再発したグレイス型甲状腺機能向上症に好ましい.
  • トータル甲状腺切除術は,一部の患者にとって有効な選択肢です.

結論:

  • 甲状腺毒性症の現在の治療法は,特にグレイヴス病の寛解率に関して,限界があります.
  • 放射性ヨウ素療法は,特に再発した症例では,重要な治療方法です.
  • 将来の研究は,ホルモンの過剰生産を管理するだけでなく,疾患プロセスを調節する新しいアプローチに焦点を当てます.